Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Last trade$239.32
Day change-$0.45 (-0.19%)
Day range$222.05 – $242.45
Volume249,386
Market cap$15.39B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$15.39B
Price / earnings
74.73×
Price / book
3.67×
Price / sales
3.26×
EV / sales
4.01×
EV / EBITDA
10.21×
Profitability
Earnings per share
$3.21
Return on assets
1.72%
Return on equity
4.91%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.33×
Current ratio
1.82×
Quick ratio
1.64×
Cash ratio
0.8×
Cash flow
Price / cash flow
9.09×
Price / free cash flow
9.96×
Free cash flow
$1.54B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for JAZZ, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$1.24B
$1.21B
$1.07B
$1.2B
$1.13B
$1.05B
$897.8M
$1.09B
Cost of revenue
$110.6M
$116.4M
$134.1M
$153.53M
$128.9M
$116.3M
$104.6M
$128.71M
Gross profit
$1.13B
$1.09B
$934.8M
$1.04B
$997.2M
$929.4M
$793.2M
$959.46M
Selling, general and administrative
$407.9M
$389.2M
$352.7M
$406.21M
$530.6M
$358.4M
$514M
$369.29M
Research and development
$211.9M
$207.5M
$196M
$213.91M
$198.2M
$189.9M
$180.7M
$240.5M
Total operating expenses
$1.55B
$843.7M
$721M
$789.86M
$939.7M
$1.62B
$849.1M
$768.69M
Operating income
-$413.4M
$248.2M
$213.8M
$254.54M
$57.5M
-$686.4M
-$55.9M
$190.77M
Interest expense
-$45.5M
-$37.1M
-$39.9M
$0
-$48.6M
-$47.4M
-$53.7M
$0
Income before taxes
-$458.9M
$210.9M
$299.2M
$208.47M
$9M
-$735.7M
-$109.8M
$133.22M
Income taxes
$24.5M
$18.1M
$6.1M
$4.96M
-$242.4M
-$17.2M
-$17.8M
-$57.91M
Net income
-$483.4M
$192.8M
$293.1M
$203.45M
$251.4M
-$718.5M
-$92.5M
$191.12M
Net income attributable to common shareholders
-$483.4M
$192.8M
$293.1M
$203.45M
$251.4M
-$718.5M
-$92.5M
$191.12M
EBITDA
$519.7M
$504.3M
$395.2M
$433.7M
$278.3M
$393M
$108.9M
$359.19M
Basic earnings per share
-$7.48
$3.05
$4.73
$3.33
$4.14
-$11.74
-$1.52
$3.16
Diluted earnings per share
-$7.48
$2.78
$4.43
$3.38
$4.08
-$11.74
-$1.52
$2.78
Recent news
Company coverage with links to the original publishers.
The American Academy of Sleep Medicine released a comprehensive report and multiyear roadmap to improve women's sleep health, identifying priority areas including fertility, pregnancy, postpartum health, menopausal transitions, and sleep disorders. The report highlights gaps in research, clinical care, and policy, calling for increased clinical trial representation, research funding, and tailored interventions for women.
Four biotechnology companies presented clinical findings and emerging treatment approaches for brain cancers at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia. NeOnc Technologies is preparing for FDA meetings on two programs (NEO100 and NEO212), Cerenome is advancing REYOBIQ therapy and diagnostic tools, Nuvation Bio is expanding data on safusidenib for IDH1-mutant gliomas, and Jazz Pharmaceuticals is progressing dordaviprone through Phase 3 trials for rare brain cancers.
The article highlights three top-ranked healthcare mutual funds with Zacks Mutual Fund Rank #1 (Strong Buy): Franklin Biotechnology Discovery (FBDIX) with 27.9% three-year annualized returns, Fidelity Select Pharmaceuticals Portfolio (FPHAX) with 20.2% returns, and Fidelity Select Biotechnology Portfolio (FBIOX) with 26.2% returns. These funds offer diversification and stability in the healthcare sector, which is considered defensive against market volatility.
Jazz Pharmaceuticals reported Q3 2026 revenue of $1.24 billion, up 10.4% year-over-year and beating consensus estimates by 2.56%. However, EPS came in at -$3.88 versus $8.13 a year ago. While some product lines like Zepzelca (+31.7%) and Ziihera (+148%) showed strong growth, others like Epidiolex (-2.4%) and oxybate products (-3.3%) declined. The stock has underperformed the market, down 8.4% over the past month, and carries a Zacks Rank #4 (Sell) rating.
Ultragenyx is expected to report a quarterly loss of $0.88 per share with revenues of $184.25 million for Q3 2026. Despite a significant 82.52% upward revision in EPS estimates over the last 30 days, the company's Earnings ESP of -22.56% combined with a Zacks Rank #3 makes it difficult to predict an earnings beat. The company has beaten consensus estimates only once in the last four quarters.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.